Radiopharm Theranostics Ltd ADR RADX 深 滬
等待開盤 07-18 09:30:00 美东时间
4.47
+0.020
+0.45%
華盛通- 最 高4.75
- 今 開4.75
- 成交量 1.95万股
- 最 低 4.24
- 昨 收 4.45
- 總市值 3477.62万
- 52周最高 50.82
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3.4962
- 委 比 0.00%
- 總股本 777.99万
- 歷史最高 50.82
- 量 比 1.96
- 振 幅 11.46%
- 歷史最低 3.4962
- 每 手 1
- 風險率 1.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia
Radiopharm Theranostics has signed a supply agreement with Cyclotek to produce RAD 402, a放射性药物 for prostate cancer treatment, labeled with Terbium-161. The Phase 1 clinical trial, supported by this agreement, is expected to begin in the second half of 2025. RAD 402 targets KLK3, with potential improved therapeutic efficacy compared to existing treatments. This collaboration aims to bring an innovative treatment option to prostate cancer patients.
06-24 12:00
Radiopharm Theranostics Advances Prostate Cancer Trial with Cyclotek Partnership
An announcement from Radiopharm Theranostics Limited ( ($AU:RAD) ) is now avail...
06-24 09:17
Radiopharm Theranostics Announces Change in Substantial Holder Interests
The latest update is out from Radiopharm Theranostics Limited ( ($AU:RAD) ). Ra...
06-16 15:18
Radiopharm Theranostics Issues New Shares, Ensures Compliance
Radiopharm Theranostics Limited ( ($AU:RAD) ) just unveiled an announcement. Ra...
06-12 07:27
Radiopharm Theranostics' RAD101 Receives FDA Fast Track Designation For Imaging Brain Metastases
Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today
06-11 20:10
Radiopharm Theranostics Announces New Securities Issue
Radiopharm Theranostics Limited ( ($AU:RAD) ) has provided an announcement. Rad...
06-10 15:48
Radiopharm Theranostics Initiates Phase 1 Trial for Novel Cancer Treatment
An announcement from Radiopharm Theranostics Limited ( ($AU:RAD) ) is now avail...
06-04 07:27
Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake
Radiopharm Theranostics announced preclinical data for their Lu177-B7H3-mAb RV01, showing favorable biodistribution, high tumor uptake, and a shorter half-life compared to traditional monoclonals, potentially reducing off-target exposure. The data support advancing RV01 to a first-in-human basket study in solid tumors, with an IND submission expected mid-2025 and Phase 1 initiation by year-end. RV01 targets the B7H3 receptor, highly expressed in ...
06-02 12:00
Radiopharm Theranostics Advances RV01 Program with Promising Preclinical Data
Radiopharm Theranostics Limited ( ($AU:RAD) ) has provided an update. Radiophar...
06-02 08:28
Radiopharm Theranostics Director Increases Shareholding
The latest announcement is out from Radiopharm Theranostics Limited ( ($AU:RAD)...
05-30 16:49
